Please login to the form below

Not currently logged in
Email:
Password:

GSK agrees Rwanda access to generic HIV drugs

UK-based GlaxoSmithKline (GSK) has given consent through Canada's Access to Medicines Regime to enable local pharmaceutical firm Apotex to manufacture a generic fixed dose combination antiretroviral, containing GSK's patented active ingredients zidovudine and lamivudine for the treatment of HIV/AIDS in Rwanda.

UK-based GlaxoSmithKline (GSK) has given consent through Canada's Access to Medicines Regime to enable local pharmaceutical firm Apotex to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing GSK's patented active ingredients zidovudine and lamivudine for the treatment of HIV/AIDS in Rwanda.

Canada's Access to Medicines Regime allows the government to authorise the production of certain patented medicines for export. The legislation includes controls which are designed to ensure that these essential medicines reach the patients for whom they are intended and the authorisation to be granted will be subject to these controls.

GSK has agreed to waive royalties as long as Apotex's triple combination generic anti-retroviral will be supplied on a strictly not-for-profit basis.

CEO for GSK Canada, Paul Lucas, said: "Tackling the AIDS crisis is one of the greatest challenges the world faces. GSK continues to play its part to tackle this crisis through research and development, not-for-profit pricing and ongoing investment in dedicated community programmes. Our decision to allow Apotex to manufacture an FDC containing two GSK molecules is part of this broad commitment."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics